|
1
|
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.
|
Haematologica
|
2008
|
2.99
|
|
2
|
Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.
|
Haematologica
|
2005
|
2.87
|
|
3
|
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.
|
Blood
|
2007
|
2.77
|
|
4
|
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
|
Blood
|
2008
|
2.74
|
|
5
|
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
|
Cancer Res
|
2006
|
1.67
|
|
6
|
Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders.
|
Cytometry B Clin Cytom
|
2010
|
1.36
|
|
7
|
Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma.
|
Blood
|
2004
|
1.26
|
|
8
|
Multifunctional role of Erk5 in multiple myeloma.
|
Blood
|
2005
|
1.22
|
|
9
|
Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.
|
Blood
|
2002
|
1.21
|
|
10
|
Conventional diagnostics in multiple myeloma.
|
Eur J Cancer
|
2006
|
1.20
|
|
11
|
Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
|
Br J Haematol
|
2009
|
1.13
|
|
12
|
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.
|
Blood
|
2009
|
1.10
|
|
13
|
Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.
|
Haematologica
|
2009
|
1.08
|
|
14
|
Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents.
|
Br J Haematol
|
2003
|
1.02
|
|
15
|
Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect.
|
Br J Haematol
|
2002
|
0.97
|
|
16
|
Bortezomib is an efficient agent in plasma cell leukemias.
|
Int J Cancer
|
2005
|
0.93
|
|
17
|
Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire.
|
Cancer
|
2006
|
0.87
|
|
18
|
Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease.
|
Int J Cancer
|
2009
|
0.80
|
|
19
|
Immunophenotypic and cytogenetic comparison of Waldenstrom's macroglobulinemia with splenic marginal zone lymphoma.
|
Clin Lymphoma
|
2005
|
0.79
|
|
20
|
Cell cycle analysis of Waldenstrom's macroglobulinemia.
|
Clin Lymphoma
|
2005
|
0.75
|